NCT02694822View on ClinicalTrials.gov

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

March 30, 2022

Study Completion Date

March 31, 2022

Conditions
Advanced Solid CancersAdvanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies
Interventions
DRUG

Zalifrelimab

An anti-CTLA-4 monoclonal antibody.

Trial Locations (11)

28204

Levine Cancer Institute, Charlotte

33136

University of Miami Miller School of Medicine, Miami

43210

The Ohio State University Comprehensive Cancer Center, Columbus

60611

Comprehensive Cancer Center of Northwestern University, Chicago

70121

Ochsner Cancer Institute, New Orleans

75702

Texas Oncology, Tyler Texas, Tyler

78705

Texas Oncology - Austin Midtown, Austin

80218

Rocky Mountain Cancer Center, Denver

90033

USC Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope National Medical Center, Duarte

07962

Atlantic Health System/Morristown Medical Center, Morristown

Sponsors

Lead Sponsor

Agenus Inc.
All Listed Sponsors
lead

Agenus Inc.

INDUSTRY

NCT02694822 - AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy | Biotech Hunter | Biotech Hunter